跳至主要内容
临床试验/NCT02236962
NCT02236962Unknown不适用

Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological Treatment

Bayside Health1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2012年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
42
试验地点
1
主要终点
brown adipose tissue activity

研究概览

简要总结

Obesity is epidemic in Australia, and current preventative strategies have had limited success in alleviating this health crisis. While numerous options are available for treatment of obesity, most do not result in sustained weight reduction. Obesity results from an imbalance between energy intake and expenditure, therefore new methods that correct this imbalance are essential for effective long-term treatment. Rodent studies show that brown adipose tissue (BAT) can burn more energy than any other tissue in the body, therefore targeting BAT to increase its activity (energy burning rate) and quantity in humans is potentially a powerful tool for the treatment of obesity and related diseases. BAT has only recently been irrefutably identified in adult humans therefore little is known about how it functions in humans.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
19 Years 至 35 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Males aged 19 - 35 years
  • Free of overt coronary disease (on history, medical examination and ECG)
  • Unmedicated
  • No major illness
  • BMI <27 kg/m2

排除标准

  • Unable to give informed consent
  • Participant in research projects involving ionising radiation within the past 5 years.
  • Claustrophobia
  • Fasting plasma glucose > 6.0 mmol/L

研究组 & 干预措施

Placebo

Placebo Comparator

lactose powder in equivalent capsule

干预措施: Placebo (Drug)

Drug treatment

Experimental

sympathetic agonist and thiazolidinedione

干预措施: Ephedrine, pioglitazone (Drug)

结局指标

主要结局

brown adipose tissue activity

时间窗: 3 years

measured via PET-CT

次要结局

未报告次要终点

研究者

发起方
Bayside Health
申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验